Viewing Study NCT05113251

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 11:47 PM
Ignite Modification Date: 2026-02-24 @ 5:08 AM
Study NCT ID: NCT05113251
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-11-18
First Post: 2021-10-22
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer
Sponsor: AstraZeneca
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Breast Neoplasms View
None Breast Cancer View
None HER2-positive Early Breast Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Trastuzumab Trastuzumab Deruxtecan (T-DXd; DS-8201a) View
None DESTINY-BREAST11 View
None Receptor, ErbB-2 View
None breast neoplasms View
None Antineoplastic Agents, Phytogenic View
None Antineoplastic Agents;Molecular Mechanisms of Pharmacological Action View
None DB11 View
None Enhertu View
None HER2 (human epidermal growth factor receptor 2) View
None breast cancer View